Share chart Merck & Co
Extended chart
Simple chart
About Merck & Co
Merck & Co., Inc. действует как медицинская компания по всему миру. Он работает через два сегмента: фармацевтический сегмент и сегмент ветеринарии. Фармацевтический сегмент предлагает фармацевтические продукты для здоровья человека в областях онкологии, неотложной помощи в больницах, иммунологии, неврологии, вирусологии, сердечно-сосудистой системы, диабета и женского здоровья, а также вакцины. more detailsMain settings
IPO date
1978-01-13
ISIN
US58933Y1055
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
3.86
Див.доход ап
9.78
Дивиденд ао
0.81
Дивиденд ап
0.0228
Сайт
Grade
Underestimation
Title | Value | Grade |
P/S | 3.9 | 4 |
P/BV | 5.4 | 2 |
P/E | 14.6 | 8 |
Efficiency
Title | Value | Grade |
ROA | 18.61 | 6 |
ROE | 40.81 | 10 |
ROIC | 22.77 | 7 |
Dividends
Title | Value | Grade |
Dividend yield | 3.21 | 8.03 |
DSI | 0.9286 | 9.29 |
Average dividend growth | 7.4 | 10 |
Debt
Title | Value | Grade |
Debt/EBITDA | 1.38 | 8 |
Debt/Ratio | 0.4802 | 10 |
Debt/Equity | 0.6687 | 9 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | 33.71 | 5 |
Yield Ebitda, % | 197.35 | 10 |
Yield EPS, % | 142.31 | 10 |
Dividends
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
1.04% | 0.81 | IV кв. 2024 | 14.03.2025 | 17.03.2025 | 01.04.2025 |
3.14% | 3.117 | III кв. 2024 | 13.12.2024 | 16.12.2024 | 31.12.2024 |
0.76% | 0.77 | II кв. 2024 | 13.09.2024 | 16.09.2024 | 01.10.2024 |
0.6% | 0.77 | I кв. 2024 | 14.06.2024 | 17.06.2024 | 02.07.2024 |
0.59% | 0.77 | IV кв. 2023 | 12.03.2024 | 14.03.2024 | 29.03.2024 |
0.66% | 0.73 | II кв. 2023 | 12.09.2023 | 14.09.2023 | 29.09.2023 |
0.66% | 0.73 | I кв. 2023 | 12.06.2023 | 14.06.2023 | 29.06.2023 |
0.67% | 0.73 | IV кв. 2022 | 10.03.2023 | 14.03.2023 | 29.03.2023 |
0.76% | 0.69 | II кв. 2022 | 12.09.2022 | 14.09.2022 | 29.09.2022 |
0.75% | 0.69 | I кв. 2022 | 10.06.2022 | 14.06.2022 | 29.06.2022 |
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 79.29 $ | 0 $ | 0 $ | -0.29 % | 0 % | 0 % |
Week | 81.82 $ | 78.28 $ | 79.29 $ | -3.37 % | 0 % | 0 % |
Month | 77.58 $ | 76.17 $ | 81.82 $ | 1.91 % | 0 % | 0 % |
Three month | 79.18 $ | 73.47 $ | 89.76 $ | -0.15 % | 0 % | 0 % |
Half a year | 87.28 $ | 73.47 $ | 101.02 $ | -9.42 % | 0 % | 0 % |
Year | 118.45 $ | 73.47 $ | 132.96 $ | -33.25 % | 0 % | 0 % |
3 years | 87.38 $ | 73.47 $ | 132.96 $ | -9.52 % | 0 % | 0 % |
5 years | 72.53 $ | 68.81 $ | 132.96 $ | 9 % | 0 % | 0 % |
10 years | 59.53 $ | 46.75 $ | 132.96 $ | 32.8 % | 0 % | 0 % |
Year to date | 84.42 $ | 73.47 $ | 101.02 $ | -6.35 % | 0 % | 0 % |
Insider trading
Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
Smart Dalton E. III SVP Fin. - Global Controller |
25.04.2025 | 29.04.2025 | Sale | 82.76 | 352 723 | 4262 | 0 | 0 | link |
Smart Dalton E. III SVP Fin. - Global Controller |
25.04.2025 | 29.04.2025 | Purchase | 58.08 | 290 400 | 5000 | 0 | 0 | link |
Williams David Michael EVP,Chief Info&Digital Officer |
13.02.2025 | 13.02.2025 | Sale | 85.34 | 512 040 | 6000 | 0 | 0 | link |
Oosthuizen Johannes Jacobus President, U.S. Market |
08.02.2025 | 11.02.2025 | Purchase | 87.28 | 1 134 820 | 13002 | 0 | 0 | link |
Oosthuizen Johannes Jacobus President, U.S. Market |
04.05.2024 | 06.05.2024 | Purchase | 127.51 | 116 289 | 912 | 0 | 0 | link |
Klobuchar Michael A EVP - Chief Strategy Officer |
04.05.2024 | 06.05.2024 | Purchase | 127.51 | 113 101 | 887 | 0 | 0 | link |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth |
04.05.2024 | 06.05.2024 | Purchase | 127.51 | 3 458 840 | 27126 | 0 | 0 | link |
Merck & Co., Inc. 10% Owner |
11.03.2024 | 11.03.2024 | Purchase | 23 | 492 136 000 | 21397205 | 0 | 0.85 | link |
Davis Robert M Chairman, CEO & President |
14.02.2024 | 15.02.2024 | Sale | 125.4 | 10 661 600 | 85021 | 0 | 0 | link |
Davis Robert M Chairman, CEO & President |
14.02.2024 | 15.02.2024 | Purchase | 73.73 | 6 268 600 | 85021 | 0 | 0 | link |
Davis Robert M Chairman, CEO & President |
13.02.2024 | 15.02.2024 | Sale | 125.85 | 18 877 500 | 150000 | 0 | -0.01 | link |
Davis Robert M Chairman, CEO & President |
13.02.2024 | 15.02.2024 | Purchase | 74.18 | 11 127 000 | 150000 | 0 | 0.01 | link |
Davis Robert M Chairman, CEO & President |
28.04.2023 | 28.04.2023 | Sale | 114.93 | 16 472 800 | 143329 | 0 | -0.01 | link |
Davis Robert M Chairman, CEO & President |
28.04.2023 | 28.04.2023 | Purchase | 56.04 | 8 032 160 | 143329 | 0 | 0.01 | link |
Main owners
Institutions | Volume | Share, % |
Vanguard Group Inc | 244 776 747 | 9.66 |
Blackrock Inc. | 201 836 434 | 7.97 |
State Street Corporation | 116 865 977 | 4.61 |
Wellington Management Group, LLP | 85 595 999 | 3.38 |
Geode Capital Management, LLC | 55 428 245 | 2.19 |
FMR, LLC | 42 800 017 | 1.69 |
Morgan Stanley | 40 129 825 | 1.58 |
Bank of America Corporation | 37 994 581 | 1.5 |
Charles Schwab Investment Management, Inc. | 36 682 866 | 1.45 |
Price (T.Rowe) Associates Inc | 30 087 217 | 1.19 |
Contained in ETF
Similar companies
P/E & P/BV
Company management
Head | Job title | Payment | Year of birth |
Ms. Jennifer L. Zachary | Executive VP & General Counsel | 2.73M | 1978 (47 years) |
Ms. Caroline Litchfield | Executive VP & CFO | 2.8M | 1969 (56 years) |
Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer | N/A | 1969 (56 years) |
Mr. Robert M. Davis J.D. | Chairman, President & CEO | 6.08M | 1967 (58 years) |
Mr. Peter Dannenbaum | Vice President of Investor Relations | N/A | |
Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories | 3.44M | 1963 (62 years) |
Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller | N/A | 1967 (58 years) |
Mr. Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health | 1963 (62 years) | |
Mr. Sanat Chattopadhyay | Executive VP & President of Merck Manufacturing Division | 1960 (65 years) | |
Ms. Cristal N. Downing | Executive VP and Chief Communications & Public Affairs Officer | 1969 (56 years) |
About company
Address: United States, Kenilworth, 2000 Galloping Hill Road - Open in google maps, Open in yandex maps
Website: http://www.merck.com
Website: http://www.merck.com